VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
-1.75%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$741M
AUM Growth
+$71.4M
(+11%)
Cap. Flow
+$90.9M
Cap. Flow
% of AUM
12.26%
Top 10 Holdings %
Top 10 Hldgs %
60.46%
Holding
153
New
4
Increased
99
Reduced
7
Closed
6
Top Buys
| 1 |
Marathon Petroleum
MPC
|
$24M |
| 2 |
ETP
Energy Transfer Partners, L.P.
ETP
|
$17.4M |
| 3 |
WPZ
Williams Partners L.P.
WPZ
|
$12.1M |
| 4 |
BPL
Buckeye Partners, L.P.
BPL
|
$9.09M |
| 5 |
Enterprise Products Partners
EPD
|
$8.33M |
Top Sells
| 1 |
OKS
Oneok Partners LP
OKS
|
$34.2M |
| 2 |
CEQP
Crestwood Equity Partners LP
CEQP
|
$1.61M |
| 3 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
$1.6M |
| 4 |
Plains All American Pipeline
PAA
|
$1.55M |
| 5 |
Fidelity MSCI Financials Index ETF
FNCL
|
$1.45M |
Sector Composition
| 1 | Energy | 73.6% |
| 2 | Healthcare | 7.94% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
CytomX Therapeutics
CTMX
$350M
| $437K | 0.06% |
24,077
+2,202
| +10% | +$40K |
|
102
Agios Pharmaceuticals
AGIO
$1.92B
| $430K | 0.06% |
6,435
+588
| +10% | +$39.3K |
|
103
Iovance Biotherapeutics
IOVA
$785M
| $423K | 0.06% |
54,523
+4,987
| +10% | +$38.7K |
|
|
AGEN
104
Agenus
AGEN
$134M
| $417K | 0.06% |
4,816
+441
| +10% | +$38.2K |
|
|
LJPC
105
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $412K | 0.06% |
11,845
+1,084
| +10% | +$37.7K |
|
|
XLRN
106
DELISTED
Acceleron Pharma Inc.
XLRN
| $410K | 0.06% |
10,977
+1,004
| +10% | +$37.5K |
|
|
LOXO
107
DELISTED
Loxo Oncology, Inc
LOXO
| $407K | 0.05% |
4,413
+404
| +10% | +$37.3K |
|
|
CBIO
108
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $405K | 0.05% |
290
+27
| +10% | +$37.7K |
|
|
BLUE
109
DELISTED
bluebird bio
BLUE
| $404K | 0.05% |
227
+20
| +10% | +$35.6K |
|
|
RETA
110
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $402K | 0.05% |
12,925
+1,182
| +10% | +$36.8K |
|
111
Celldex Therapeutics
CLDX
$1.55B
| $400K | 0.05% |
9,318
+852
| +10% | +$36.6K |
|
112
Corbus Pharmaceuticals
CRBP
$120M
| $400K | 0.05% |
1,864
+171
| +10% | +$36.7K |
|
113
Karyopharm Therapeutics
KPTI
$60.5M
| $393K | 0.05% |
2,385
+218
| +10% | +$35.9K |
|
114
Prothena Corp
PRTA
$452M
| $392K | 0.05% |
6,048
+554
| +10% | +$35.9K |
|
115
PTC Therapeutics
PTCT
$4.47B
| $392K | 0.05% |
19,612
+1,794
| +10% | +$35.9K |
|
|
PRTK
116
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $370K | 0.05% |
14,726
+1,347
| +10% | +$33.8K |
|
|
GBT
117
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $368K | 0.05% |
11,845
+1,084
| +10% | +$33.7K |
|
|
CALA
118
DELISTED
Calithera Biosciences, Inc
CALA
| $367K | 0.05% |
1,166
+107
| +10% | +$33.7K |
|
119
Xencor
XNCR
$583M
| $364K | 0.05% |
15,881
+1,452
| +10% | +$33.3K |
|
120
Alaunos Therapeutics
TCRT
$4.45M
| $362K | 0.05% |
393
+36
| +10% | +$33.2K |
|
121
Novavax
NVAX
$1.2B
| $351K | 0.05% |
15,414
+1,410
| +10% | +$32.1K |
|
122
TG Therapeutics
TGTX
$5.03B
| $349K | 0.05% |
29,453
+2,694
| +10% | +$31.9K |
|
|
ACHN
123
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $348K | 0.05% |
77,433
+7,083
| +10% | +$31.8K |
|
124
MacroGenics
MGNX
$121M
| $341K | 0.05% |
18,449
+1,688
| +10% | +$31.2K |
|
125
Cytokinetics
CYTK
$6.18B
| $339K | 0.05% |
23,395
+2,140
| +10% | +$31K |
|